Topic Listing for Inogen Inc

Access Information Accrued Liabilities
Additional Enabling Technologies Adenoviral P53 Compositions Therapies
Adenovirus Production Purification Formulation Advexin
Advexin Effective Among Itt Population Advexin Exceptional Side-effect Profile
Advexin Significantly Improves Survival Tumor Responses P53 Favorable Advexin Therapy Overview Regulatory Status
Advexin Therapy Targeted Molecular Alliance Agreement Colgate-palmolive
Alliance Colgate-palmolive Amendments Articles Incorporation Bylaws Change
Background Basis Presentation
Benzimidazole Small Molecule Cancer Therapy Program Biomarkers
Business Collaborative Arrangements C0123456789
Cancer Clinical Trials Personalized Medicine Conference Cash Equivalents
Clinical Trials Combination Therapy Tumor Suppressors Including P53 Mda-7 Il24
Common Stock Grant Officers Competition
Consolidated Statements Operations Contract Services Grant Other Revenue
Contractual Obligations Conversion Preferred Stock Common
Critical Accounting Policies Current Treatment Cancer
Delivery Systems Departure Directors Certain Officers Election Appointment Compensatory
Dividend Policy Drug Approval Process
Electronic Voting Instructions Employee Stock Purchase Plan
Employment Agreement Equity Price Risk Foreign Currency Exchange Rate
Estimates Exact Name Registrant Specified Charter
Fair Value Financial Instruments Fast Track Products
Federal Income Taxes Financial Results
Financial Statements Exhibits Form 10-k
Forward-looking Statements General Administrative Expense
Highlights Improves Survival Recurrent Refractory Head Neck Cancer Patients
Index Ingn 007 Oncolytic Viral Therapy
Ingn 225 P53 Molecular Immunotherapy Ingn 234 P53 Topical
Ingn 241 Mda-7 Ingn 401 Fus-1
Ingn 402 403 Nanoparticle Formulations P53 Mda-7 Respectively Insurance Litigation
Intangible Assets Interest Expense
Interest Income Interest Rate Risk
International Introgen
Introgen Appoints James Rothman Phd Board Directors Introgen Approach
Introgen Enabling Technologies Introgen Intends Appeal Fda Decision
Introgen Receives Nasdaq Notice Regarding Minimum Market Value Introgen Receives Staff Determination Letter Nasdaq Global Market
Introgen Technical Services Introgen Therapeutics Inc
Introgen Therapeutics Reports 2008 Financial Results Recent Corporate Investment Pharma Plc
Lease Commitments London Stock Exchange
Magnum Therapeutics Corporation Manufacturing Process Development
Manufacturing Subsidiary Staffing Increased Market Equityholder Information
Marketable Securities Marketing Applications
Marketing Sales Moffitt Cancer Center
Mortgage Payable Nanoparticle Systemic Delivery Platform
Nanoscale Viral Delivery Systems National Cancer Institute
National Institutes Health Net Cash Provided Financing Activities
Net Cash Used Investing Activities Net Loss Per Share
Non-voting Not Voted Via Internet Telephone Fold Along Perforation
Off-balance Sheet Arrangements Off-label
Only Fda Emea Corresponding Regulatory Agencies Authority Approve Orphan Drug Act
Other Advexin Therapy Activities Other Events
Other Income Other Research Development Programs
Other Technology Option License Agreements Other Therapeutic Composition Process Technologies
Other Tumor Suppressors Overview
Overview Cancer Part
Patent Technology License Agreement University Texas System Pharma Plc
Portfolio Power Attorney
Pre-clinical Testing Property Equipment
Recent Accounting Pronouncements Recently Issued Accounting Pronouncements
Regulation Disclosure Replicating Viral Delivery Systems
Report Independent Registered Public Accounting Firm Research Development Costs
Research Development Expense Research Grants
Research License Agreement Mda-7 Tumor Suppressor Results Operations
Results Operations Financial Condition Revenue Recognition
Risks Uncertainties Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Share-based Compensation
Share-based Compensation Expense Shares Reserved Future Issuance
Short-term Investments Signatures
Stock Options Stock Purchase Warrants
Stock Repurchases Stock Sales
Study Design Table Contents
Targeted Therapeutics Trade Secrets
Tumor Suppressors University Texas Anderson Cancer Center
Virrx Inc World-renowned Scientist Brings Expertise Areas Oncology Personalized Medicine
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki